Eosinophilic inflammation: Severe asthma and beyond
Prof. Nikoletta Rovina E-Mail
Associate Professor in Pulmonary and Critical Care Medicine, Intensive Care Unit, 1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest, Diseases Hospital, Athens, Greece
Research Keywords: Molecular Mechanisms of Asthma and Allergy, Immunology of asthma, Biologics for Asthma Therapy, COPD
Assistant Prof. Andriana Papaioannou E-Mail
Professor in Respiratory Medicine in the 1st Respiratory Medicine Department of the School of Medicine of the National and Kapodistrian university of Athens
Research Keywords: Asthma, COPD, Biomarkers, Exacerbations, Biologics
Prof. Petros Bakakos E-Mail
Professor of Respiratory Medicine, 1st University Department of Respiratory Medicine, National and Kapodistrian University of Athens, Greece
Research Keywords: Asthma, Severe Asthma, COPD, Bronchiectasis, Airway Inflammation
In the recent years, considerable advances have been achieved in understanding the inflammatory background of eosinophilic inflammation underlying respiratory and non-respiratory diseases. Severe eosinophilic asthma represents the most studied disease entity and several new biologics have been introduced as effective treatments. However, beyond severe asthma, eosinophilic inflammation plays pivotal role in other eosinophilic diseases as well, such as in eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. Differences between asthma and other eosinophilic diseases, particularly in eosinophils homing, target organs and clinical features, probably account for the different response to treatment.
This special issue focuses on eosinophilic biology, activity, signaling, and inflammatory process and discusses possible therapeutic targets. Furthermore, mechanisms of action, as well as efficacy and safety of the use of biologics beyond severe eosinophilic asthma, are discussed, covering diseases such as EGPA, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis.
Keywords: Eosinophilic Inflammation, Severe Asthma, ABPA, EGPA, Eosinophilic Esophagitis, Mepolizumab, Reslizumab, Benralizumab.